Amid a push to win back investor confidence in its R&D trajectory, Sanofi still has significant commercial powder to burn with Dupixent, as illustrated in a third-quarter showing that looked strong by ...

Nurix Therapeutics (NASDAQ:NRIX) shares plunged 28.4% in premarket trading on Wednesday after pharmaceutical partner Sanofi ...

Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the ...

Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported in Q3 2026, but sales fell by 3% year on year to $68.3 million.

(RTTNews) - Provention Bio, Inc. (PRVB) has entered into a co-promotion agreement with Sanofi U.S. for the launch of the company's lead investigational drug candidate teplizumab. Sanofi will commit ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Sanofi reported strong third-quarter results on Friday, October 30, 2026, and raised its full-year outlook. The French ...

Belén Garijo, who took over the reins of the French pharma group in April, said this morning that Sanofi's "whole ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Today Evidation Health announced that it has closed a $10 Million funding round led by Sanofi-Genzyme BioVentures—the corporate venture capital arm of Sanofi, a ...